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Abstract: Worldwide obesity is a growing health problem, associated with increased risk of chronic disease. 
Understanding the molecular basis of adipogenesis and fat cell development in obesity is essential to identify 
new biomarkers and therapeutic targets for the development of anti-obesity drugs. microRNAs (miRNAs) 
appear to play regulatory roles in many biological processes associated with obesity, including adipocyte 
differentiation, insulin action and fat metabolism. Recent studies show miRNAs are dysregulated in obese 
adipose tissue. During adipogenesis miRNAs can accelerate or inhibit adipocyte differentiation and hence 
regulate fat cell development. In addition miRNAs may regulate adipogenic lineage commitment in multipotent 
stem cells and hence govern fat cell numbers. Recent findings suggest miR-519d may be associated with 
human obesity, but larger case-control studies are needed. Few miRNA targets have been experimentally 
validated in adipocytes but interestingly both miR-27 and miR-519d target PPAR family members, which are 
well established regulators of fat cell development. In this review recent advances in our understanding of the 
role of miRNAs in fat cell development and obesity are discussed. The potential of miRNA based therapeutics 
targeting obesity is highlighted as well as recommendations for future research which could lead to a 
breakthrough in the treatment of obesity. 
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INTRODUCTION 
Within the next five years the World Health 
Organization projections indicate approximately 2.3 
billion adults will be overweight and more than 700 
million adults will be obese. Obesity is a major risk 
factor for chronic diseases such as cardiovascular 
disease and Type 2 diabetes [1,2]. In recent years 
despite advances in understanding the molecular basis 
of obesity, anti-obesity drugs lack physiological 
specificity and have side-effects [3]. In the past decade 
the discovery of non-coding microRNAs (miRNAs) 
which can post-transcriptionally regulate thousands of 
genes has generated enormous research interest [4,5]. 
Now miRNA biomarkers have been found in many 
chronic diseases such as cancer, cardiovascular 
disease and Type 2 diabetes [4, 6-8]. Recently, 
evidence of miRNA dysregulation has been reported in 
human obesity [9]. In future miRNA biomarkers may 
assist in the early diagnosis of chronic diseases and 
also provide new therapeutic targets [10]. With recent 
advances it is a real possibility miRNA signatures from 
patient’s tissue or plasma could be used for 
personalized diagnosis and treatment [6,10]. Hence it 
is a pertinent time to review our current understanding 
of the role of miRNAs in adipogenic differentiation and 
obesity. Firstly, this review will provide a brief overview 
of the association between adipocyte biology and 
obesity. Secondly, our current understanding of miRNA 
biogenesis, regulation and function are summarized. 
Thirdly, recent advances in the role of miRNAs in fat  
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cell development and obesity are discussed based on 
mouse and human studies. Furthermore, the impact of 
extracellular factors such as inflammatory cytokines on 
adipocyte miRNAs is considered. In closing the 
potential of miRNA based therapeutics for anti-obesity 
treatments will be highlighted along with 
recommendations for future research. 
OBESITY 
Obesity is characterized by increased fat mass and 
energy storage in adipose tissue [2]. Increases in fat-
mass can be achieved by increases in the size of 
adipocytes (adipocyte hypertrophy), or expanding the 
numbers of adipocytes (adipocyte hyperplasia) [11]. In 
addition, obesity is strongly associated with 
inflammation and insulin resistance [12], although not 
always [13]. Larger fat cells are closely linked to 
greater fat mass and the production of inflammatory 
cytokines [11]. Nevertheless, alterations in adipocyte 
turnover rate, differentiation and apoptosis could all 
contribute to changes in fat mass underlying obesity. 
However, recent findings suggest the turnover rate of 
pre-adipocytes in humans is very low, amounting to 
10% self-renewal every year [14]. Other studies have 
suggested pre-adipocyte differentiation may be 
impaired in obese humans [15-17]. Larger fat cells 
attract macrophages leading to adipocyte necrosis and 
release of fatty acids into circulation which contributes 
to excess fat deposition in the liver [11]. One possible 
avenue to reduce fat mass is to therapeutically regulate 
adipocyte differentiation, but a better understanding of 
the pathways controlling adipogenesis is needed. 
In recent years, there has been a rapidly growing 
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Table 1.  Mammalian miRNAs Associated with Adipogenesis and Obesity 
 
miRNA Function  Experiment  System  Species  Targets    References 
Let-7   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad, MSC,  
Ob adipose tissue 
Ob adipocytes 
H/M 
H 
HMGA2 
E2F6 
CDC34 
[56, 58-61, 75] 
[9, 66] 
miR-15a   Adipogenesis 
 Adipose tissue 
3T3-L1 
Ob adipose tissue 
M 
H 
DLK1 [61,  72] 
[9] 
miR-17/92   Adipogenesis  3T3-L1  M  RB2 
p130 
[57, 68] 
miR-21   Adipogenesis  3T3-L1, MSC  H/M  TGFBR2  [56, 65, 76] 
miR-24   Adipogenesis    M    [64] 
miR-27   Adipogenesis 
 Adipose tissue 
3T3-L1, MSC 
Ob adipocytes 
H/M 
H/M 
PPARG 
 
[59, 68-70] 
[68, 70] 
miR-31   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-Ad 
Ob adipocytes 
H/M/R CEBPA  [56,  64,  78] 
[66] 
miR-103   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad, MSC, 
Ob adipose tissue 
H/M 
M 
PDK1 
WNT3A 
[55, 56, 59-61, 65, 75] 
[55] 
miR-107 
 
 Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad, MSC, 
Ob adipose tissue 
H/M 
M 
  [55, 56, 59, 60, 75] 
[55] 
miR-125b   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad,  
Ob adipose tissue 
Ob adipocytes 
H/M 
H/M 
 [55,  56,  66] 
[55, 66] 
miR-138   Adipogenesis  MSC  H  EID1  [77] 
miR-143   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad, MSC 
Ob adipose tissue 
H/M 
H/M 
ERK5  [55, 60, 61, 64, 75] 
[55, 62] 
miR-150   Adipogenesis 
 Adipose tissue 
3T3-L1 
Ob adipose tissue 
M 
H 
 [56] 
[9] 
miR-200   Adipogenesis  MSC  M    [80] 
miR-210   Adipogenesis 
 Adipose tissue 
3T3-L1 
Ob adipocytes 
M 
H 
TCF7L2 [56,  59,  65] 
[66] 
miR-221   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad 
Ob adipose tissue 
M 
H/M 
 [55] 
[55, 66] 
miR-222   Adipogenesis 
 Adipose tissue 
3T3-L1, Pre-ad 
Ob adipose tissue 
M 
M 
 [55] 
[55] 
miR-326   Adipogenesis 
 Adipose tissue 
Pre-ad 
Ob adipose tissue 
R 
H 
 [78] 
[66] 
miR-355   Adipogenesis 
 Adipose tissue 
3T3-L1, MSC 
Ob adipose tissue 
H/M 
M 
- [59,  63,  75] 
[63] 
miR-378   Adipogenesis  3T3-L1, MSC  M    [56] 
miR-448   Adipogenesis  3T3-L1  M  KLF5  [71] 
miR-519d   Adipose tissue  Ob adipose tissue  H  PPAR [9] 
Pre-ad – Pre-adipocytes; Ob – Obese; MSC – Multipotent mesenchymal stem cells; H – Human; M – Mouse; R – Rat. 
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and obesity [18,19]. Studies have showed miRNA 
expression in pre-adipocytes is altered during fat cell 
development and in obesity (Table 1). Understanding 
the role miRNAs play in the proliferation and 
differentiation of adipocytes during fat cell development 
could provide new therapeutic targets for anti-obesity 
drugs. In addition, identifying miRNAs dysregulated 
during the development of obesity, could provide early 
obesity biomarkers for clinical diagnosis. 
miRNAs 
miRNAs are a class of short non-coding RNAs (19-
22 nucleotides) involved in the post-transcriptional 
regulation of genes [20]. miRNAs can bind to 
complementary target sites in mRNA genes which can 
cause translation repression or cause cleavage, 
deadenylation and degradation of target mRNA genes 
[21]. miRNAs may regulate over one third of protein-
coding genes, for example, overexpression of specific 
miRNAs in HeLa cells revealed hundreds of transcripts 
are modulated, but the down-regulated transcripts were 
more likely to contain conserved miRNA binding sites 
[22]. Further studies have shown widespread regulation 
of protein levels by miRNAs in cellular and animal 
models [23,24], yet the true magnitude of post-
transcriptional regulation by miRNAs in humans is 
unknown. Computational predictions suggest 45000 
putative miRNA binding sites may exist in human 
protein coding genes [25]. However, many of the 
putative miRNA binding sites remain to be 
experimentally validated. 
miRNA BIOGENESIS AND PROCESSING 
Understanding of miRNA biogenesis and regulation 
has advanced rapidly in recent years and has been 
reviewed elsewhere [20,26,27]. miRNAs are 
transcribed from intronic or intergenic regions, while 
some miRNAs are encoded within protein coding 
genes [20]. The main steps in the miRNA processing 
pathway are illustrated in Fig. (1). miRNAs are 
transcribed as longer primary miRNA (pri-miRNA) 
transcripts by RNA polymerase II and processed into 
functional mature miRNAs by miRNA processing 
proteins [26]. In the nucleus pri-miRNA sequences are 
cleaved by a microprocessor complex including the 
RNAase III enzyme Drosha and DGCR8, which results 
in shorter 70-80 nucleotide precursor miRNAs (Pre-
miRNA) [28]. Precursor miRNAs are rapidly exported 
from the nucleus to the cytoplasm mainly via Exportin5 
which is a GTP dependent nuclear transport protein 
[29]. In the cytoplasm pre-miRNAs are processed by 
the Dicer, leaving an unstable miRNA duplex which 
unwinds, the 5’ guide strand containing the mature 
miRNA sequence is incorporated into a ribonucleotide 
silencing complex (RISC) while the 3’ passenger strand 
is rapidly degraded [30]. 
The RISC consist of multiple proteins, many of 
which remain to be fully characterized [31]. Argonaute 
proteins contain multiple GW182 binding sites which 
facilitate miRNA localization to cytoplasmic P-bodies 
[27]. The mammalian homologue of GW182 is TNRC5 
which regulates miRNA processing in human cells. P-
bodies contain deadenylases and decapping enzymes 
such as CAF1 and PABP which can cause adenylation 
and degradation of target mRNAs [32]. P-bodies can 
also act as temporary storage depots for mRNAs and 
therefore reduce the translation of mRNAs into proteins 
[32]. 
miRNAs are generally reported to have long half-
lives, but little is known about the mechanism which 
regulates miRNA degradation in cells. XRN-2 which is 
a 53 exoribonuclease has been reported to mediate 
the degradation of mature miRNAs in Caenorhabditis 
elegans, but no studies have examined miRNA 
degradation in human cells [33-35]. Elucidating the 
mechanism leading to miRNA degradation could 
explain the downregulation of miRNAs in some chronic 
diseases such as Type 2 diabetes and provide new 
therapeutic targets to restore miRNA homeostasis   
[36]. 
REGULATION OF miRNA PROCESSING 
miRNA processing may be regulated by multiple 
factors [27]. Some miRNAs are processed efficiently, 
while other miRNAs show large discrepancies between 
pre- and mature-miRNA abundance [37]. Alterations in 
miRNA processing proteins Drosha and Dicer can 
cause widespread decreases in mature miRNAs and 
have been associated with cancer [38]. However, 
recent advances are revealing more sensitive and 
selective factors exist which can regulate miRNA 
processing [27]. 
miRNAs can be transcriptionally regulated by 
proteins binding upstream of miRNA genes [26]. For 
example SMAD proteins are reported to bind to the 
genomic region encoding miR-21 and suppress miR-21 
transcription [39]. miRNAs can also be post-
transcriptionally regulated by RNA-binding proteins 
[26]. For example, hnRNP-A1 (heterogeneous nuclear 
ribonucleoprotein A1) can bind to pre-miR-18a and 
block further processing by Drosha [40]. Furthermore, 
in embryonic stem cells LIN28 protein can bind to a 
conserved region in the miRNA stem loop encoding let-
7, which leads to inhibition of Drosha activity, thus 
preventing embryonic stem cell differentiation [41]. 
Intriguingly, 14% of all pri-miRNAs are reported to have 
highly conserved stem loops, which suggests these 
may act as landing pads for RNA-binding proteins [42] 
and hence provide a further regulatory layer in the 
miRNA processing pathway. 
RNA binding proteins can also disrupt miRNA target 
sites for example DND1 (Dead end 1) can bind to 
miRNA target sites in the 3’UTR hence blocking miRNA 
binding and miRNA-mediated translational repression 
[43]. To date existing evidence suggests mature 
miRNA expression is tightly regulated by multiple 
factors including RNA-binding proteins and miRNA 
processing proteins [27], but so far there have been no microRNAs in the Regulation of Adipogenesis and Obesity  Current Molecular Medicine,  2011, Vol. 11, No. 4     307 
studies on the regulation of the miRNA biogenesis 
pathway in adipocytes. 
IDENTIFICATION OF miRNA TARGETS 
miRNAs are important post-transcriptional 
regulators of gene expression because an individual 
miRNA can target hundreds of genes [20]. Therefore, 
several miRNAs can act combinatorially to regulate a 
network of target genes. miRNA target genes can be 
computationally predicted based on several factors 
[20]. Mature miRNAs contain a seed region between 
nucleotide 2-7 which can bind to complementary 
sequences in the 3’UTRs of target genes [44]. Perfect 
complementarity between miRNA seed sequence and 
3’UTR increases the likelihood of target repression, but 
imperfect seed matches can also lead to target 
repression [44]. miRNA target prediction algorithms are 
widely available, which can predict miRNA targets 
across different species [45]. The most established and 
widely used miRNA target prediction algorithms are 
TargetScan [44], PicTar [46] and Miranda [47]. Each 
uses a different set of rules to identify and evaluate the 
efficacy of a miRNA target using a unique scoring 
system [45]. Evaluating the utility of each prediction 
algorithm is difficult as there is no comprehensive set of 
experimentally validated targets [20]. Furthermore, it is 
possible miRNAs which normally repress translation 
can also activate translation of target mRNAs 
depending on cell cycle [48]. Currently, there is still 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). miRNA biogenesis pathway. miRNAs are transcribed by RNA polymerase II resulting in pri-miRNA transcripts. Pri-
miRNAs are processed by a microprocessor complex including Drosha and DGCR8 leaving Pre-miRNAs which are exported 
from the nucleus via Exportin5. Pre-miRNAs are processed by Dicer, the mature miRNA is loaded in the RISC complex. Mature 
miRNAs bind the 3’UTRs of target mRNAs and localize to P-bodies. In P-bodies target mRNAs are deadenylated and degraded 
via CAF1 and PABP or translationally repressed. 
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debate whether miRNAs predominantly act via 
translational repression or mRNA degradation of 
targets, which has important implications for designing 
studies to validate predicted miRNA targets [20]. 
Several studies suggest miRNAs may predominantly 
function  via  mRNA cleavage and hence could be 
detectable by genome-wide microarrays [22-24]. 
Unfortunately there are no universally accepted criteria 
for validating miRNA targets [49]. 
EXPERIMENTAL VALIDATION OF miRNA 
TARGETS 
Experimental validation of miRNA targets involves 
measuring changes in predicted target proteins in 
response to ectopic miRNA expression or miRNA 
knockdown. In addition, it is important to demonstrate a 
miRNA can specifically bind to its predicted target 
gene. Typically, miRNA: mRNA target binding can be 
demonstrated by transfecting a miRNA inhibitor or 
miRNA mimic alongside a Luciferase reporter 
containing the 3’UTR of the predicted target mRNA 
[49]. Novel approaches to measuring global changes in 
miRNA targets are possible by microarray profiling of 
RNA bound to immunoprecipitated Argonaute proteins 
[50]. Alternatively, global target protein changes in 
response to cellular miRNA manipulation can be 
tracked using stable isotope labeling with amino acids 
in cell culture (SILAC) techniques [23]. Whichever 
approach is used, the consensus among miRNA 
researchers is that experimental validation of predicted 
miRNA targets remains necessary to confirm the 
functional relationship between a miRNA and its target 
mRNA [20]. 
miRNA MUTANTS CHARACTERIZED BY AN 
OBESE PHENOTYPE  
The first evidence of a role for miRNAs in fat cell 
metabolism and obesity came from genetic screens in 
Drosophila [51]. miR-14 deletion in Drosophila caused 
the development of a phenotype characterized by 
apoptosis, enlarged adipocyte lipid droplets, elevated 
triglycerides and diacylglycerol [51]. These findings 
suggested miR-14 plays a role in fat metabolism and 
cell death. A later study reported mutant miR-278 
Drosophila were characterized by a lean phenotype 
with reduced adiposity [52]. The miR-278 mutants also 
had high circulating sugar levels despite elevated 
insulin production, which suggested lack of miR-278 
may lead to insulin resistance [52]. Ectopic expression 
of the EX (Expanded) gene which can act as a tumor 
suppressor and also harbors a putative miR-278 target 
site resulted in a similar phenotype to the miR-278 
mutants [52]. Although these studies implicated 
miRNAs in fat metabolism, cell death and insulin 
resistance, neither miR-278 nor miR-14 have known 
human homologs and therefore have not been 
subsequently examined in obese humans. 
miRNAs AND ADIPOCYTE DIFFERENTIATION 
In adipose tissue increased fat mass associated 
with obesity is characterized by both increased 
adipocyte size and/or increased adipocyte number [11]. 
The process of adipogenesis largely determines the 
number of adipocytes in body fat depots. Pre-
adipocytes proliferate and can develop into mature 
adipocytes upon growth arrest, clonal expansion and 
terminal differentiation [53]. Mature adipocytes are 
insulin sensitive and can store large amounts of lipids 
[53]. Another source of pre-adipocytes is multipotent 
MSCs (Fig. 2). These multipotent MSCs can develop 
into lineage committed pre-adipocytes upon hormonal 
stimulation and differentiate into mature lipid storing 
adipocytes [54]. Currently the role of multipotent MSCs 
in the development of human obesity is unclear. 
To date studies have profiled miRNA expression 
during adipogenic differentiation predominantly in the 
mouse 3T3-L1 cell-line [55-59]. Studies have used 
miRNA arrays in combination with validation by 
Northern blot or RT-qPCR, but with no universally 
accepted miRNA array platform there is little 
agreement between studies on candidate miRNAs 
(Table  2) [18]. Some miRNAs appear to be negative 
regulators of adipocytes differentiation while some 
miRNAs are capable of accelerating adipocyte 
differentiation [18,19]. 
 
 
 
 
 
 
 
 
 
Fig. (2). Fat cell development: Multipotent mesenchymal stem cells can develop into lineage committed pre-adipocytes. PPAR 
and C/EBP transcription factors co-ordinate adipogenic gene expression during terminal differentiation into lipid storing mature 
adipocytes. 
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miRNAs CAN ACCELERATE ADIPOCYTE 
DIFFERENTIATION 
A screening study of adipogenic miRNAs using 
ASO (anti-sense oligonucleotides) directed at a large 
panel of miRNAs in human primary sub-cutaneous pre-
adipocytes revealed inhibition of miR-9* and miR-143 
suppressed the adipogenic markers GLUT4, HSL, 
FABPaP2, PPAR-2 and triglyceride accumulation [60]. 
miR-143 is also reported to be strongly induced during 
pre-adipocyte 3T3-L1 differentiation [55,61,58] and 
human pre-adipocyte differentiation [60]. Ectopic miR-
143 expression during differentiation of 3T3-L1 pre-
adipocytes resulted in twice the level of triglyceride 
accumulation early during differentiation [55]. There 
have been few reports of experimental validation of 
miR-143 targets in adipocytes. 
One study demonstrated ERK5 (Extracellular-
signal-regulated kinase 5) is targeted by miR-143 in 
human pre-adipocytes [60]. The role of ERK5 in 
adipocyte differentiation is not clear, although it has 
been suggested ERK5 suppression may be involved in 
fine-tuning the MAPK (mitogen activated protein 
kinase) pathway to maintain the differentiated state 
[55]. In a high-fat diet model of obesity miR-143 was 
found to be upregulated in mesenteric adipose tissue of 
mice, yet only a modest downregulation of miR-143 
target protein ERK5 was observed in-vivo [62]. If miR-
143 is pro-adipogenic then developing miR-143 
inhibitors may be a useful approach to slow down 
adipocyte differentiation and lipid droplet formation. 
Ideally studies are needed to determine whether 
triglyceride accumulation can be altered by miR-143 
inhibition in mature adipocytes. 
Several other miRNAs have been identified which 
can accelerate adipocyte differentiation [55, 56, 59, 61, 
63-65]. miR-103 is reported to be upregulated during 
differentiation of human pre-adipocytes [60]. When 
miR-103 is overexpressed in the presence of 
adipogenic stimuli, adipogenesis accelerates, as shown 
by increased triglyceride accumulation and adipogenic 
gene expression [55]. In-vivo miR-103 was reported to 
be downregulated in mature adipocytes from obese 
mice [55], although studies in obese human  adipose 
tissue show miR-103 is upregulated [9, 66]. The lack of 
consistency between studies is most likely due to 
differences in fat depots between mice and humans. It 
appears more experimental work is needed to establish 
the role of miR-103 in adipogenesis and obesity. 
The miR-17/92 cluster is reported to be significantly 
upregulated during 3T3-L1 differentiation [57]. The 
miR-17-92 cluster consists of five members, miR-17-
5p, miR-17-3p, miR-18, miR-19b and miR-20, of which 
only miR-20 was previously reported to be upregulated 
in mature differentiated adipocytes [60]. The miR-17-92 
cluster appeared to target Rb2 and p130, which are 
both negative regulators of differentiation. 
Overexpression of the miR-17-92 cluster was reported 
to translationally repress Rb2 and p130 resulting in 
rapid adipocyte differentiation [57]. 
Clonal expansion in 3T3-L1 pre-adipocytes is 
reported to be inhibited by Let-7 [67], although Let-7 
increases during later adipocyte differentiation. Clonal 
expansion usually follows growth arrest and involves 
the replication of pre-adipocytes prior to terminal 
differentiation. Ectopic expression of Let-7 markedly 
reduces HMGA2 which is a high mobility group (HMG) 
protein. HMG proteins function as architectural factors 
and are essential components of the enhancesome. In 
mice lacking HMGA2 adipose tissue is significantly 
reduced [67]. Furthermore, overexpression of HMGA2 
in obese leptin deficient mice reduces adipose tissue 
mass [67]. To date elevated HMGA protein has not 
been reported in human obese adipose tissue. 
Another adipogenic miRNA to emerge recently is 
miR-210 which has been demonstrated to regulate 
TCF712 (Fig. 3), which is a key transcription factor 
modulating components of WNT signaling [59]. 
Overexpression of miR-210 in 3T3-L1 cells is reported 
to stimulate adipocyte hypertrophy and lipid droplet 
formation [59]. The upregulation of miR-210 during 
adipogenesis is in concordance with a suppression of 
Table 2.  miRNA Microarray Platforms Used in Adipogenesis and Obesity Studies 
 
Model Platform  References 
3T3-L1  Microfluidic biochip (LC Sciences) 
Invitrogen Ncode miRNA array 
Ambion miRNA probes/Nexterion E slides 
Agilent miRNA array 
Ambion mirVana probes/Custom slides 
[55] 
[57] 
[56] 
[59] 
[65] 
Multi-potent MSCs  Exiqon miRCURY array  [78] 
Primary Adipocytes  Custom oligo/Codelink slides  [60] 
Adipose Tissue  Microfluidic biochip (LC Sciences) 
Taqman miRNA assay human panel 
Agilent miRNA array 
Exiqon miRCURY LNA miRNA array 
[55] 
[88] 
[66] 
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genes encoding proteins in the WNT signaling pathway 
[59]. 
miRNAs CAN SUPPRESS ADIPOCYTE 
DIFFERENTIATION 
Some studies have focused on miRNAs which 
appear to act as negative regulators of adipocyte 
differentiation (Fig. 3). For example, overexpression of 
miR-27a in 3T3-L1 pre-adipocytes suppresses PPAR 
expression and adipocyte differentiation [68]. The 
3’UTR of PPAR harbors a putative miRNA binding 
site, which has been shown to specifically bind to miR-
27a using a luciferase reporter assay [68]. Another 
family member, miR-27b is also downregulated during 
adipocyte differentiation. MiR-27b can also bind to the 
3’UTR of PPAR and repress PPAR protein levels 
[69]. However, transfection of miR-27b two days after 
adipogenic stimulation was not sufficient to repress 
PPAR protein in 3T3-L1 adipocytes [68]. Interestingly, 
in mature adipocytes from obese mice lower miR-27a 
expression has been found compared to lean mice, 
indicating miR-27a downregulation may be necessary 
for adipocyte hypertrophy [70]. These studies suggest 
the miR-27 family could be a useful anti-adipogenic 
target. Potentially miR-27a mimics could be used to 
regulate pre-adipocyte proliferation. However, 
suppressing mature adipocyte differentiation and the 
concomitant reduction of lipid storage capacity may 
lead to lipids being stored in liver and skeletal muscle 
with detrimental side-effects such as insulin resistance 
or steatosis [11]. 
Another study reported miR-448 is a potential 
inhibitor of adipogenesis [71]. miR-448 is encoded 
within the intron of HTR2C, a serotonin receptor which 
is upregulated during 3T3-L1 adipocyte differentiation 
[71]. Kruppel-like factor 5 (KLF5) contains a putative 
miR-448 binding site which was experimentally 
validated using a luciferase reporter assay. 
Overexpression of miR-448 in pre-adipocytes 
suppresses KLF5, triglyceride accumulation and 
adipogenic gene expression thus suggesting miR-448 
is a negative regulator of adipocyte differentiation [71]. 
Inhibition of miR-15a appears to reduce pre-
adipocyte size while promoting adipocyte proliferation 
[72]. In preadipocytes miR-15a has been shown to 
target Delta homologue 1 (DLK1) at mRNA and protein 
level [72]. Inhibition of miR-15a in pre-adipocytes 
resulted in a decrease in cell size along with an 
increase in cell number [72]. Despite many published 
miRNA profiling studies in 3T3-L1 pre-adipocytes, 
mouse and human pre-adipocytes only one other study 
reported miR-15a was upregulated during pre-
adipocyte differentiation [61]. More studies are needed 
to fully delineate the role of miR-15a in adipocyte 
proliferation in humans. 
In summary, to date studies have identified several 
candidate miRNAs which can accelerate or inhibit pre-
adipocyte differentiation (Table 2). These miRNAs may 
provide promising candidates to design anti-obesity 
drugs to control fat cell development. However, it 
remains important to examine whether miRNAs which 
regulate adipocyte differentiation in-vitro are 
dysregulated in human obesity in-vivo. Another source 
of pre-adipocytes which could increase mature 
adipocyte numbers and hence contribute to fat mass is 
multipotent MSCs (Fig. 2). 
miRNAs AND MULTIPOTENT MESENCHYMAL 
STEM CELLS DURING ADIPOGENESIS 
Multipotent MSCs are fibroblast-like cells present in 
multiple tissues such as bone marrow but with potential 
to differentiate into diverse cell types including 
adipocytes, osteocytes and chondrocytes [73]. 
Unfortunately, multipotent MSCs are difficult to define 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Mammalian miRNAs regulate target genes during adipogenesis. 
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due to the lack of established cellular markers [54]. 
Furthermore, the factors governing the adipogenic 
lineage commitment of multipotent MSCs have not 
been well characterized [74]. Adipogenic lineage 
commitment can be activated by developmental factors 
such as BMP (Bone-morphogenic protein) resulting in 
the development of an adipo-fibroblast type cell. 
Mesenchymal stem cell derived pre-adipocytes can 
subsequently undergo terminal differentiation into 
mature adipocytes (Fig. 2).  
Bone marrow is a rich source of multipotent MSCs, 
the vascular stroma of adipose tissue also harbors 
multipotent MSCs [73]. Studies in the last two years 
have reported miRNA expression is altered during 
adipogenic lineage commitment of multipotent MSCs 
[56, 64, 68, 69, 75-78]. Upregulation of adipogenic 
lineage commitment in the multipotent MSC population 
could contribute to adipocyte hyperplasia in obesity. 
However to date the contribution of multipotent MSCs 
to increased adipose tissue mass in obesity is largely 
unknown. 
Mouse Studies 
Opposing effects of miR-24 and miR-31 have been 
reported in the C3H10T1/2 multipotent mouse 
embryonic stem cell line treated with BMP2 to induce 
adipogenic differentiation [64]. Neither miR-24 nor miR-
31 alone was sufficient to alter development of 
multipotent MSCs to mature adipocytes, but in the 
presence of BMP2, miR-24 overexpression accelerated 
mature adipocyte marker expression, while miR-31 
overexpression suppressed the adipogenic markers 
PPARG, CEBPA and aP2 [64]. A putative miR-31 
binding site in the 3’UTR of CEBPA was experimentally 
validated [64]. CEBPA is an enhancer binding protein 
which can bind to the promoter of leptin. Therefore, 
miR-31 downregulation could indirectly suppress leptin 
via  translational repression of CEBPA during 
adipogenic lineage commitment of MSCs [64]. 
Leptin is a well-established adipose hormone which 
regulates appetite and fat storage [79]. However, leptin 
mimics developed as anti-obesity agents have been 
unsuccessful to date, due to leptin resistance in obese 
humans [3]. Interestingly, according to the miRNA 
target finding algorithm TargetScan the 3’UTR of leptin 
harbors putative miRNA binding sites for miR-9, miR-
490, miR-29 family, miR-27 family and miR-128 [44]. In 
addition, the 3’UTR of the leptin receptor gene contains 
putative binding sites for the miR-200 family and the 
miR-30 family [44]. However, these putative miRNA 
binding sites remain to be experimentally validated. In 
future studies it may be worthwhile investigating 
whether these miRNAs can modulate leptin resistance 
and hence the efficacy of leptin-associated anti-obesity 
drugs. 
Further studies in mouse ST2 mesenchymal stem 
cells showed that expression of the mammalian miRNA 
cluster consisting of miR-141, miR-200a, miR-200b, 
miR-200c and miR-429 is upregulated during 
adipogenic differentiation [80]. This miRNA cluster has 
been shown to be a negative regulator of WNT 
signaling which blocks adipogenic differentiation in 
multipotent MSCs [80]. Further work in the ST2 
mesenchymal cell-line demonstrated overexpression of 
miR-378/378* could increase lipid droplet size 
independently of C/EBP isoforms and PPAR1 which 
are known to stimulate increases in lipid droplet size 
[56]. Conversely, knockdown of miR-378/278* 
decreased triglyceride accumulation [56]. Interestingly, 
miR-378/378* is encoded within the intron of PGC-1 
and is highly induced during differentiation of mouse 
3T3-L1 pre-adipocytes and mouse pre-adipocytes [56]. 
These findings suggest miR-378 inhibitors could 
potentially suppress differentiation of both multi-potent 
MSCs and pre-adipocytes and hence reduce the pool 
of mature lipid storing adipocytes. 
Human Studies 
Several studies have reported screening miRNA 
changes during adipogenic differentiation of human 
multipotent mesenchymal stem cells [54, 60, 66, 69, 
75, 77]. Unlike mouse MSCs miR-31 and miR-24 were 
not reported to be altered during adipogenic 
differentiation of human multipotent MSCs [75, 76]. 
Twenty miRNAs were identified as upregulated during 
adipogenic differentiation of human multipotent MSCs, 
but only one miRNA was downregulated [75]. 
Leukemia inhibitor factor (LIF) mRNA was found to be 
a direct target of two miRNAs, miR-199 and miR-346. A 
luciferase reporter construct containing the 3’UTR of 
LIF showed miR-199 and miR-346 could both bind 
putative target sites in LIF [75]. LIF is a pleiotropic 
cytokine implicated in the maintenance of stem cells 
[75]. 
Another recent study in human multi-potent MSCs 
reported miR-21 transiently increased during early 
adipogenic differentiation [76]. Overexpression of miR-
21 in human multi-potent MSCs promoted adipogenic 
differentiation [76]. TGFBR2 was demonstrated to be a 
bone-fide miR-21 target. Furthermore, miR-21 was 
found to alter SMAD3 phosphorylation, and involved in 
TGF- signaling which is known to inhibit adipocyte 
differentiation [76]. 
miRNAs may also inhibit adipogenesis in human 
multi-potent MSCs. For example, miR-138 is reported 
to be downregulated during adipogenic differentiation 
[77]. In addition, overexpression of miR-138 in human 
multi-potent MSCs during adipogenesis could 
effectively reduce lipid droplet accumulation [77]. MiR-
138 has been demonstrated to target the 3’UTR of EID-
1, an interacting inhibitor of differentiation that can 
interact with SHP, an endogenous enhancer of 
adipogenic PPAR2 [77]. Therefore miR-138 appears 
to indirectly regulate PPAR, an established  
transcription factor driving adipogenic gene expression 
in human MSCs [11]. 
Studies in human and mouse MSCs have 
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adipogenic lineage commitment which suggests MSCs 
have the potential to contribute to adipocyte 
hyperplasia in obesity. However, to date no studies 
have established whether dysregulation of multipotent 
MSCs occurs with increased adipose tissue mass and 
obesity. 
miRNAs IN BROWN ADIPOCYTES 
Adipose tissue contains both white and brown 
adipocytes. Recent findings suggest brown adipocytes 
are derived from distinct precursors closely related to 
skeletal muscle [81]. Brown adipocytes have a 
phenotype distinct from white adipocytes characterized 
by high energy expenditure rather than energy storage 
[82]. Brown adipose tissue is present in mice and 
recent findings suggest active brown adipose tissue 
may be present in humans [83, 84]. Brown adipose 
tissue appears to be negatively associated with BMI 
and body fat [83, 84]. Interestingly, miR-455 which is 
expressed at low levels in white preadipocytes and 
white mature adipocytes is reported to be upregulated 
during brown pre-adipocyte differentiation [85]. In 
addition, miR-1, miR-133a and miR-206 which are 
highly expressed in skeletal muscle [86] are reported to 
be absent from white adipocytes but are expressed in 
brown pre-adipocytes and mature adipocytes [85]. 
Further studies delineating miRNAs differentially 
regulated in brown adipocytes and miRNA targets in 
brown adipocytes could identify useful therapeutic 
targets to treat obesity. In future it may be worthwhile 
investigating whether transfecting brown adipocyte 
miRNAs into white adipocytes can shift cells towards 
an energy consuming brown adipocyte phenotype. 
EXTRACELLULAR FACTORS CAN REGULATE 
miRNAs IN ADIPOCYTES 
Cytokines 
Obesity is associated with inflammatory cytokine 
release from adipose tissue and elevated inflammatory 
cytokine levels including TNF- and IL-6 [2]. Chronic 
inflammation alters miRNA levels in immune cells [87], 
but few studies have examined the relationship 
between chronic inflammation and miRNA levels in 
adipocytes. TNF- release from adipocytes has been 
reported to impair pre-adipocyte differentiation in obese 
subjects and hence contribute to lipid deposition in liver 
and skeletal muscle [15]. However, limited data exists 
on the effects of TNF- on miRNA expression in 
differentiated adipocytes. TNF- treatment of 
differentiated adipocytes downregulated miR-103 and 
miR-143 expression, although the mechanism 
responsible remains unknown [55]. 
Release of inflammatory cytokines from adipose 
tissue attracts macrophages to adipose tissue but may 
also increase insulin resistance in peripheral tissues 
[11]. A study comparing miRNA expression in human 
subcutaneous and omental (visceral) adipose tissue 
found negative correlations between miR-99a, miR-325 
and IL-6 concentration [88]. In addition, adiponectin 
concentration was inversely correlated with miR-181a 
expression [88]. However, the aforementioned study 
included a small group of Type 2 diabetes patients. 
Future studies are needed to establish the mechanism 
linking TNF-, IL-6 and other cytokines to adipocyte 
miRNA expression. 
Glucose 
Incubation of 3T3-L1 adipocyte cells in glucose is 
reported to upregulate miR-29 and increase insulin 
resistance [89]. Another study in 3T3-L1 adipocytes 
confirmed miR-29 was induced by exposure to high 
extracellular glucose, in addition miR-27a and miR-222 
were also found to respond to extracellular glucose 
concentration [90]. A further study reported miR-320 
along with fifty other miRNAs was upregulated in 
response to hyperglycemia and hyperinsulinemia in 
3T3-L1 adipocytes [91]. Inhibition of miR-320 in insulin 
resistance 3T3-L1 adipocytes was found to improve 
insulin sensitivity and insulin-stimulated glucose uptake 
via modulation of p85 expression, phosphorylation of 
Akt and GLUT4 protein levels [91]. 
It is unknown whether glucose modulates adipose 
miRNA expression in-vivo. In human adipocytes 
glycosylated haemoglobin (HbA1c), a marker of long 
term hyperglycemia, was negatively correlated with 
miR-17-5p and miR-134 expression, but positively 
correlated with miR-181a expression [88]. Only miR-
132 was associated with fasting glucose levels in 
mature human adipocytes [88]. Again these findings 
require further confirmation in an experimental model. 
These studies suggest adipose miRNA expression may 
respond to changes in macronutrient availability. 
High-Fat Diet  
There is limited knowledge on how diet influences 
miRNA expression in adipose tissue. Experiments in 
3T3-L1 cells and primary adipocytes suggest changes 
in miRNA expression may occur in response to nutrient 
availability [89, 91]. For example, miR-143 was 
reported to be upregulated in mesenteric fat of mice fed 
a high-fat diet for 8 weeks [62]. The upregulation of 
miR-143 in mesenteric fat was associated with body 
weight, plasma leptin concentration, PPAR mRNA and 
aP2 mRNA levels [62]. In another study of high-fat diet 
fed mice, pri-miR-27a was reported to be 
downregulated in mature adipocytes [70], although one 
caveat is that pri-miRNA levels are not always 
consistent with functional mature miRNA levels [37]. 
Nevertheless the downregulation of pri-miR-27a in 
mice consuming a high-fat diet is consistent with the 
anti-adipogenic effect of miR-27a reported in 3T3-L1 
cells [70]. Given the growing number of adipogenic and 
anti-adipogenic miRNAs identified, it is highly plausible 
these miRNAs will also respond to dietary changes. 
Some studies have shown nutrient supplementation 
can reduce the adverse consequences of a high-fat 
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in adipose tissue [92, 93]. In future studies it will be 
interesting to determine whether miRNA inhibitors or 
mimics can block the development of obesity in high-fat 
diet fed mice. Furthermore, it will be interesting to 
determine whether current dietary compounds known 
to suppress diet-induced obesity also influence adipose 
miRNA expression. 
miRNAs ALTERED IN MAMMALIAN OBESE 
ADIPOSE TISSUE 
In adipose tissue from obese mouse models and 
obese humans several miRNA profiling studies have 
identified miRNAs associated with obesity [9, 55, 66, 
88]. The findings of these studies are summarized in 
Table  1. In adipose tissue of obese mice increased 
miR-143 expression is associated with parallel 
alterations in PPAR and aP24 which are markers of 
adipocyte differentiation [62], although an earlier study 
reported downregulation of miR-143 in obese mice 
[55]. However, the latter study used the epididymal fat 
pad [55] rather than the mesenteric fat pad [62] which 
may explain the lack of concordance between studies. 
In three murine models of obesity including leptin 
deficient ob/ob mice, leptin receptor deficient db/db 
mice and KKAy44 mice, miR-335 was found to be 
upregulated [63]. During adipocyte differentiation miR-
335 is strongly induced, suggesting miR-335 may play 
a role increasing the mature adipocyte population [63]. 
Despite strong correlations between fat weight and 
miR-335 expression in obese mice, there are no 
experimentally validated targets of miR-335 in 
adipocytes. To date miR-335 has not been identified in 
miRNA profiling of adipose tissue from obese humans 
(Table 1). 
In human subcutaneous adipose tissue 
overexpression of miR-519d was reported to be 
associated with severe obesity [9]. MiR-519d was 
demonstrated to bind to the 3’UTR of PPAR. Despite 
PPAR mRNA being highly expressed in obese 
subjects, PPAR protein was undetectable compared 
to controls [9]. The discrepancy between mRNA and 
protein expression indicated a post-transcriptional 
mechanism may be regulating PPAR protein. During 
adipogenesis miR-519d is stimulated in a dose-
dependent manner, which suggests miR-519d may be 
a factor in adipocyte hypertrophy and increased 
adipose tissue mass in human obesity [9]. No previous 
studies have reported miR-519d is differentially 
expressed in obesity or during adipogenic 
differentiation (Table 1). One possible explanation may 
be because biopsies from adipose tissue can consist of 
heterogeneous cell types such as, pre-adipocytes, 
mature-adipocytes, macrophages and multi-potent 
MSCs. Hence the diversity of cell types could confound 
interpretation of miRNA expression in obese adipose 
tissue across different studies. 
Also in subcutaneous adipose tissue from obese 
subjects miR-150 was reported to be upregulated and 
miR-659 was reported to be downregulated [9]. 
PPARGC1 is a predicted target of miR-150, while 
IRS2 and CPT1 are predicted targets of miR-659 
according to TargetScan [44]. Unfortunately, miR-150 
and miR-659 target protein levels were found to be 
unchanged in obese adipose tissue [9], although this 
finding does not rule out the possibility miR-150 and 
miR-659 may act on alternative targets which remain to 
be identified. 
In future miRNA profiling studies on obese adipose 
tissue, it will be important to consider differences 
between fat depots. A recent study reported omental 
and subcutaneous adipose tissue appear to have 
unique miRNA expression profiles [88]. These findings 
are in-line with past studies indicating differences in 
gene expression between subcutaneous and visceral 
fat depots, and increased production of inflammatory 
cytokines in visceral fat depots [11]. Furthermore, fat 
cell development appears to differ between fat depots, 
for example adipocyte hypertrophy was found in 
abdominal fat depots while adipocyte hyperplasia was 
observed in femoral fat depots [94]. Many additional 
miRNAs identified in these miRNA profiling studies on 
human obese adipose tissue remain to be investigated 
further [9, 66]. 
CIRCULATING miRNAs 
In the past year circulating miRNAs have generated 
much research interest as novel diagnostic disease 
markers [8]. Distinct serum and plasma miRNA 
signatures have been reported in cancer [95] and other 
chronic medical conditions. miRNAs in serum and 
plasma although usually expressed at low levels are 
detectable by real-time quantitative PCR due to the 
high sensitivity of this method to detect mature miRNA 
expression [96]. Circulating miRNAs appear not to be 
simply benign disease biomarkers. For example, 
extracellular miRNAs appear to be secreted in small 
membrane vesicles called exosomes and hence 
protect miRNAs from degradation [97]. It also appears 
that tumor-suppressive miRNAs can be transported to 
recipient cells and cause gene target silencing in 
recipient cells [97]. However, the mechanism 
responsible for secretion and transport or miRNAs has 
not been well characterized. To date no studies have 
examined whether a distinct plasma miRNA signature 
is associated with obesity. 
miRNA BASED THERAPEUTIC APPROACHES 
FOR TARGETING OBESITY 
Antagomirs have been used successfully in mice to 
downregulate miR-122 [98]. Antagomirs are anti-sense 
oligonucleotide sequences conjugated with cholesterol 
which can be injected into mice tail veins and inhibit 
specific miRNAs in liver [98]. In non-human primates 
systematic administration of LNA anti-miRs against 
miR-122 was reported to result in a dose dependent 
improvement of plasma cholesterol with no indication of 
hepatic toxicity [99]. Currently, Phase II trials are 
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SPC3649, a miR-122 targeted drug, for treatment 
of Hepatitis C virus (HCV) infection in humans [100]. To 
date there are no known miRNA therapeutics designed 
to reduce fat mass in obesity, but clearly the 
technology to inhibit miRNAs in different tissues is 
advancing rapidly. 
In a mouse model of obesity and diabetes a 
molecular autoregulatory system was developed to 
target the BDNF (brain-derived neurotrophic factor) 
gene which is involved in the regulation of energy 
balance in the hypothalamus [101]. The autoregulatory 
system consisted of a single recombinant adeno-virus 
vector harboring two expression cassettes containing 
sequences for BDNF and the sequence of a specific 
miRNA targeting BDNF [101]. The miRNA cassette 
was controlled by a promoter agouti-related protein 
which was sensitive to BDNF changes [101]. In mice as 
body weight decreased, the promoter in the miRNA 
cassette was activated inhibiting transgene expression 
of BDNF [101]. The autoregulatory approach was able 
to maintain weight loss, thus may be a plausible 
technique for long-term treatment of obesity [101]. 
CONCLUSIONS 
miRNA profiling studies have identified miRNAs 
involved in adipogenesis and associated with obesity, 
but the challenge remains to determine how these 
miRNAs are regulated in adipose tissue. Therefore, it 
would be worthwhile to investigate if there are parallel 
changes in miRNA transcription, biogenesis and 
degradation which can explain the dysregulated 
miRNAs observed in obesity. Furthermore, the role of 
other extracellular stresses and nutrient availability 
regulating obesity associated miRNAs remains 
unknown. From a clinical point of view with the recent 
discovery miRNAs are secreted into extracellular fluids, 
it will be important to establish whether a plasma 
miRNA profile can distinguish healthy and obese 
subjects. Potentially plasma miRNA profiles could be 
used by clinicians for obesity management and to track 
the efficacy of miRNA based therapeutics. Finally, 
further identification and characterization of miRNAs 
associated with adipogenesis and obesity should 
provide a new generation of therapeutic targets which 
will help facilitate the development of new anti-obesity 
treatments. 
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